**Statement of Work (SOW) SP 23-022**

**SEROLOGICAL ANALYSIS within the study “Repeated Dose Study in Minipigs with Oral Patches including 2 Weeks Recovery”**

This SOW is subject to the terms as defined in the contract between Allero Therapeutics and VRI “COLLABORATION FRAMEWORK AGREEMENT” (2023).

SP 23-022; Repeated Dose Study in Minipigs with Oral Patches including 2 Weeks Recovery

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx.

Budget specification for SOW SP 23-022:

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxx **EUR**

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxxxxxxxxxxx

**xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx**

xxxxxxxxxxxxxxxx xxxxx **EUR**

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxxx xxxxx **EUR**

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxx **EUR**

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxxxxxxxx xxx **EUR**

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

xxxxxx

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

**Total 17 500 EUR**

The budget specification is valid until December 31, 2023.

Costs charged shall be paid to VRI by bank transfer. Bank transfer details will be included in the invoice.

VRI will invoice 100% of the total financial amount after approval of the Full Final report by Allero with due date of the Invoice of 30 days after the issue date.

The serum samples are scheduled to be received from SCANTOX A/S, Denmark in week 26,

2023. VRI will be committed to provide a Draft report of the results no later than in week 31,

2023, to SCANTOX A/S, Denmark. If the serum samples are received later than in week 26,

VRI and Allero will discuss in good faith the delivery time of the Draft report

The Full Final report will be submitted by VRI 40 working days after the receiving of samples from SCANTOX A/S, Denmark. Then Allero has 14 days to approve the Full Final report. The approval will take place in a verifiable form.

This SOW shall become effective upon the Effective Date and shall terminate by December 31, 2023.

Allero and VRI note and make it undisputable that according to Czech legislation, Act No. 340/2015 Coll., to have the SOW become valid and effective, it must be disclosed in the Register of contracts. Therefore, the Parties have agreed this Agreement becomes valid on the date of its signature by the Parties and effective as of the day of its disclosure in the Register of contracts pursuant to the previous sentence. VRI shall file this Agreement at the aforementioned Register immediately after the last signature. The Parties are obliged to determine and highlight those provisions, which constitute their trade secret and thus will be exempt from the obligation of public disclosure.

Allero Therapeutics and Veterinary Research Institute agree with budget specification.

**Allero Therapeutics BV**

seated at: Marconistraat 16, 3029AK Rotterdam, The Netherlands and established on 16 April 2019 under Dutch law. ID 74606239. Tax identification No: NL859965661B01.

represented by Mr. Emil Pot, CEO and “bestuurder”, together with its affiliated companies, such as Allero Therapeutics BV, Belgium.

xxxxxxxxxxxxx

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date:

**Veterinary Research Institute**

seated at: Hudcova 296/70, Brno, Postal Code: 62100, Czech Republic

ID: 00027162

Tax identification No.: CZ00027162

xxxxxxxxxxxxxxxxxxxxxxxxxx\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date: